|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.
|
8375015 |
1993 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A mutation in the NQO1 gene had previously been demonstrated in a cancer cell line with reduced NQO1 activity.
|
8528266 |
1995 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The effect of the genetic polymorphism of acetyltransferases (NAT1) and NAT2), glutathione S-transferase M1 (GSTM1) and NAD(P)H: quinone oxidoreductase 1 (NQO1) on the risk of pancreatic diseases (cancer, pancreatitis) was examined in a case-control study.
|
9696930 |
1998 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The possible association between NQO1 genetic polymorphism and lung cancer risk was examined among 95 male smokers without cancer and 100 male smokers with lung cancer in Taiwan.
|
10591487 |
1999 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAD(P)H:(quinone acceptor) oxidoreductase (NQO1) is an antioxidant enzyme with particular relevance to cancer.
|
10910079 |
2000 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
There was no difference in the frequencies of the mutated NQO1 allele (NQO1*2): 0.190 for control individuals and 0.195 for cancer patients, respectively (P=0.947).
|
10663383 |
2000 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In laboratory animals treated with various environmental chemicals, inhibition of NQO1 metabolism has long been known to increase the risk of toxicity or cancer.
|
11882782 |
2002 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.
|
12439220 |
2002 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T was reportedly associated with leukemia, lung cancer, colorectal cancer, and urological malignancies.
|
12018106 |
2002 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We studied clonal haemopoiesis, telomere length and NQO1 status in 146 patients receiving conventional chemotherapy for non-myeloid malignancies.
|
15198733 |
2004 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Therefore, we also analyzed whether environmental and genetic factors associated with DNA damage, i.e. smoking and polymorphisms in the genes involved in the metabolism of genotoxic carcinogens (EPHX1, GSTA1, GSTM1, GSTP1, GSTT1, NAT1, NAT2 and NQO1) or DNA repair (APE1, NBS1, XPC, XPD, XRCC1, XRCC3 and XRCC4), could modify the association between telomere length and cancer risk.
|
15746160 |
2005 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Neither dicoumarol nor curcumin dissociated the complexes of NQO1 and the human cancer hot-spot p53 R273H mutant and therefore did not induce degradation of this mutant.
|
15809436 |
2005 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A sequence variant at position 609 (C --> T) in the NQO1 gene encodes an enzyme with reduced quinone reductase activity in vitro and thus was hypothesized to affect cancer susceptibility.
|
16702380 |
2006 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group.
|
18024413 |
2007 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan.
|
17619904 |
2008 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
NQO1 C609T genetic polymorphism was reported to be associated with an increased risk for cancers, including breast cancer.
|
19360290 |
2009 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The gene coding for NQO1 has a single nucleotide polymorphism (C-->T) at nucleotide position 609 (proline to serine substitution at position 187 in amino acid sequence (P187S)) (rs1800566) of the NQO1 cDNA which results in very low enzimatic activity, so it would be expected that individuals with the homologous NQO1 C609T polymorphism would have a susceptibility developing cancer.
|
21133623 |
2010 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Malignancies with NQO1*2 may be resistant to radiation and chemotherapy with resulting poorer survival.
|
21479364 |
2011 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NQO1 is an emerging and promising therapeutic target in cancer therapy.
|
22848731 |
2012 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Meta analysis of NQO1 polymorphism also indicated null association of the polymorphism with EC overall or with cancer cases stratified by tumor histopathology/ethnicity.
|
22770696 |
2012 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The functional polymorphism (rs1800566) in the NQO1 gene, a 609C>T substitution, leading to proline-to-serine amino-acid and enzyme activity changes, has been implicated in cancer risk, but individually published studies showed inconclusive results.
|
22272361 |
2012 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This meta-analysis suggested that Ser allele of NQO1 Pro187Ser significantly contributed to the increased risks of colorectal adenoma and cancer in Caucasians.
|
22306249 |
2012 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The NRF2-activated cytoprotective proteins (NAD(P)H dehydrogenase quinone 1 and glutamine-cysteine ligase catalytic subunit) were expressed in all of the cancers with KEAP1 mutations.
|
22348534 |
2012 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The results of combined analyses indicated that the T allele of NQO1 C609T was significantly associated with increased risk of DT cancer [odds ratio (95% CI): 1.58 (1.22-2.07) for TT vs. CC and 1.13 (1.06-1.22) for T carriers vs. C carriers].
|
22387672 |
2012 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
NQO1 C609T polymorphism was thoroughly investigated with respect to cancer susceptibility.
|
23860519 |
2013 |